/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization.
I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021 ycharts.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ycharts.com Daily Mail and Mail on Sunday newspapers.
SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ I-Mab , a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel. | December 3, 2021
SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been dosed in the U.S. phase 2 dose expansion clinical study of its proprietary CD73 antibody uliledlimab (also known as TJD5).
/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization.